HNSCC remains a major medical issue with only two targeted therapies approved to date, the chimeric anti-EGFR monoclonal antibody (mAb) cetuximab and recently anti-PD-1 mAbs. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.